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The known challenge of underutilization of data and biological material from biorepositories as potential resources
for medical research has been the focus of discussion for over a decade. Recently developed guidelines for improved
data availability and reusability—entitled FAIR Principles (Findability, Accessibility, Interoperability, and
Reusability)—are likely to address only parts of the problem. In this article, we argue that biological material and data
should be viewed as a unified resource. This approach would facilitate access to complete provenance information,
which is a prerequisite for reproducibility and meaningful integration of the data. A unified view also allows for
optimization of long-term storage strategies, as demonstrated in the case of biobanks. We propose an extension of the
FAIR Principles to include the following additional components: (1) quality aspects related to research reproduc-
ibility and meaningful reuse of the data, (2) incentives to stimulate effective enrichment of data sets and biological
material collections and its reuse on all levels, and (3) privacy-respecting approaches for working with the human
material and data. These FAIR-Health principles should then be applied to both the biological material and data. We
also propose the development of common guidelines for cloud architectures, due to the unprecedented growth of
volume and breadth of medical data generation, as well as the associated need to process the data efficiently.
Keywords: FAIR (Findable, Accessible, Interoperable, and Reusable) principles, provenance information
management, privacy protection, open science, quality, incentives
Introduction
Inefficient sharing of data
1 generated from public
funding and increasing dependence of research domains on
data have led to the development of specific guidelines such as
the FAIR data principles: Findable, Accessible, Interoper-
able, and Reusable.2 While the FAIR principles (Fig. 1) are a
good starting point, applicable to various domains of science,
they are not specific enough to deal with the major challenges
of medical research, namely reproducibility and privacy
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protection. We propose a unified view of biological material
and data together with specific extensions to the FAIR data
principles, to boost their use and reuse in medical research.
These FAIR-Health principles include the following three
main components: (1) quality and traceability; (2) incentive
schemes; and (3) privacy regulation compliance. FAIR-
Health principles are also applicable to other fields dealing
with health-related and sensitive personal data, such as so-
cial sciences.
Biobanks: A Unified View of Biological Material,
Expertise, and Data
The European Biobanking and BioMolecular resources
Research Infrastructure, BBMRI-ERIC,* anticipates sub-
stantial potential in the ability of biobanks to completely
integrate the chain, from research participants and their data/
samples all the way to research results (Fig. 2).
Biobanks consist of the following key components: (1)
repositories of biological material retrieved as samples from
the research participants; (2) metadata describing repositories
and stored samples; (3) data accompanying the samples
(medical records, including imaging data and lifestyle data);
(4) data generated from the samples (e.g., omics data and
imaging data); (5) expertise in various fields related to long-
term preservation and analyses of biological material and
data, ethical/legal expertise; and (6) additional services
related to biobanks as infrastructure (e.g., sample hosting,
processing, and curation).3–5 Many biobanks are intended
as facilities for long-term use, and thus research can ad-
ditionally benefit from the extensive possibilities of lon-
gitudinal sample and data acquisition, such as samples/data
from the same donor at different time points for studies
concerning disease or treatment markers.
With current analytic and data collection techniques ca-
pable of generating almost unlimited amounts of data on each
research participant donating samples and data, the question
naturally arises as to whether it is meaningful, sustainable,
and even technically feasible to collect, validate, store, and
curate all the data on a long-term basis, and whether the
volume of data is what will make medical and biomedical
research more productive in the future.
As part of the strategy to address these issues, BBMRI-
ERIC proposes a unified view of biological material and
the data generated from the material, since biological ma-
terial can be considered biological data storage/a biological
data source. The biological material and data custodians
can thus apply different strategies when combining storage
to achieve acceptable costs: large raw data may be un-
derstood as transient data that can be regenerated if the
original material is still available and its integrity is pre-
served in the long-term storage; hence, only relatively
small resulting data may be kept together with the original
material. We additionally argue that the high-level principles
of FAIR-Health should also be applied to the biological
material. The only specific aspects of biological material
are that it varies in its properties and is depletable (except
FIG. 1. FAIR data principles.
*www.bbmri-eric.eu
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for amplifiable derivatives, such as cell cultures or DNA),
and therefore of limited accessibility (namely subject to
access prioritization).
Translation of research results to medically meaning-
ful knowledge and products suffers from substantial re-
producibility issues.6–13 Recently, this has stimulated the
proposal of countermeasures that are technically infeasible,
such as an idea to store all the intermediate data used for
publications14, Rule 5. Although recognizing that primary
biological material and data have to be stored for the sake of
‘‘reconstructing’’ results, which need to comply with prin-
ciples of Good Research Practice,{ it is, however, not
practical and sometimes not even feasible to store all the
data, due to the sheer volume of all the intermediate data.
It can even be argued that storing intermediate data is of
limited use when exploring reproducibility of the results, for
example because of undocumented or proprietary formats.
Furthermore, reproducibility15 needs a clear link from
the research participant (or other sources of nonhuman bi-
ological material), through the physical material and all
the preanalytical steps, including sample stabilization and
biobanking, to the data generated and published. Such links
can be implemented using provenance information man-
agement systems16 (see Fig. 3 for background information
on provenance). Incorporation of the preanalytical steps as
a part of data provenance is increasingly recognized17 be-
cause the preanalytical phase has major implications on the
preservation of biomolecules, and thus on meaningfulness
of the data generated by the analysis of biological samples.
For example, RNA analysis of a biological material can be
subject to the checks of integrity of RNA molecules and
thus the overall conclusion may be that the results are
meaningful. However, the biological material, which is still
‘‘alive,’’ may have responded to the artificial environmental
conditions after its removal from its original environment,
such as after a surgical resection of a tumor{18, Annex A.
As a consequence, the material analyzed no longer rep-
resents the original material and its biological activity in the
human body. While the analysis of such material is then
performed in a technically correct manner, the results might
not be meaningful. Accordingly, a prerequisite to obtain
meaningful data requires an assessment of fitness of the
biological material, based on the provenance information,
for the purpose of the specific research and analytical
method. The reproducibility and the meaningfulness jointly
determine the quality of the biological material and data
(Fig. 4). The advantage of infrastructures providing a unified
view of physical material and data, such as biobanks, is that
they can integrate provenance information naturally.
As part of quality improvement efforts, it is also necessary
to document syntax, semantics, and history of data as com-
pletely as possible. This is particularly important for types of
data that have been collected primarily for the purpose of
healthcare, but can still be reused for research as a ‘‘sec-
ondary use,’’ namely lawful use that requires fulfilling
FIG. 2. The flow of data and samples from the research participants to biobanks, and then to researchers. Note the
particular aspect of matching informed consent provided by the research participant to the research project, which can also
be substituted by an ethical board decision if consent is not available.
{www.esf.org/fileadmin/Public_documents/Publications/Code_
Conduct_ResearchIntegrity.pdf in particular also deals with data
management in Good Research Practice (section 1.4) point 1, and
Guidelines for Good Practice Rules (section 2.3) point 1.
{This behavior has been documented, for example, in EU FP7
SPIDIA project (www.spidia.eu) and has become part of Annex A
of CEN/TS 16826-1:2015.18
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specific regulatory requirements, such as specifying antici-
pated secondary uses in the informed consent, or obtaining
approval from an ethics committee for the reuse of data under
specific conditions. While the data generation adheres to
medical and laboratory best practices at any given moment,
technology advances, methods evolve, and instruments are
upgraded to ensure the best standard of healthcare over time.
These changes may result in vast problems when integrating
the data into consistent data sets, particularly as semantics of
data changes over time and across various sources, such as
biorepositories, cohorts, or laboratories. These problems
stimulate the need for data models and formats that can un-
ambiguously capture syntax and semantics of the data, such as
numeric data with defined notation, units, and semantics of the
data, as well as methods used to generate such data.x
Provenance information management
Complete provenance information of any biological ma-
terial and data (Fig. 5) is important to interpret the data or to
enrich an existing biological material and data set consis-
tently. This provenance information must include a link to
the source biological material and—if possible—a link to
the information on the very research participant who do-
nated the material.
Fragmentation of healthcare information standards, par-
ticularly in clinical settings, may pose significant impedi-
ments to this process in practice.
For certain cases, it may be necessary to develop robust
distributed provenance information schemes, so that on one
hand it is possible to reconstruct the whole trail, while also
keeping the process compliant with data protection regulations
on the other. An example of such a process could be reporting
data back in case of incidental findings or if a research par-
ticipant exercises his/her right to receive the data generated
from them. Due to privacy protection requirements, this may
involve collaboration between multiple entities responsible for
different parts of the provenance information.
Q-1: Provenance information must be FAIR. This involves
development and adoption of domain-specific standards for
provenance based on commonly accepted provenance infor-
mation data models.
Q-2: Provenance information must continuously cover the
whole chain from sample to data, ideally even from the
research participant to sample, while also being compliant
with data protection regulations.
Quality as a prerequisite for extensibility
To develop comparable specimen and data collections, it
is important to describe the processes of obtaining and
manipulating the sample from the research participant to the
storage of the biological material (sometimes informally
called ‘‘from the needle to the freezer’’). For reproducibility
reasons, it is also necessary to document all the preanalytical
and analytical methods used to generate the data, as has
been demonstrated in the literature.10,17,19
Q-3: Provenance information must have sufficient tech-
nical ability to describe compliance of the biological ma-
terial with common quality standards, such as preanalytical
standards (e.g., ISO or CEN standards).
Q-4: Provenance information must include information
about analytical methods and tools used to generate data
from the biological material.
Incentives
In contrast to many other scientific fields, medical data can
only be made available to researchers because of voluntary
contribution from a variety of individuals, particularly research
participants (donors and patients) and medical doctors. A
positive incentive scheme must be developed and adopted in
wide research communities, which will maximize biological
material and data sharing and achieve actual reuse. Effective
incentive schemes will also exert pressure on resource pro-
viders to implement transparent access policies and reduce the
fragmentation of access procedures. Similar incentive princi-
ples should also be applied to software tools and their sus-
tainability, which is fundamental for any data-driven medical
research.
FIG. 3. Provenance information.
xThese developments are already reflected in efforts such as ISO
TC 276 (Biotechnology) Working Group 5 on data integration.
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The incentives schemes must implement the following
principles:
INCE-1: Incentives must be in place for all the links in
the chain: (1) biological material and data generation or
collection; (2) biological material and data storage, curation,
and enrichment; and (3) biological material and data reuse.
INCE-2: For biological material and data collections re-
ceiving public funding or infrastructural funding, the in-
centive must stimulate reuse by external users, namely users
outside the infrastructure.
INCE-3: Contributions to existing biological material and
data collections should be supported by funding organizations.
INCE-4: Academic promotion schemes and institutional
evaluation schemes should incorporate contributing to and
reuse of existing biological material and data collections.
Curation of biological material and data in INCE-1 needs
to be understood as a more complex process, and not just the
updating of data formats. This includes increasing its extent,
as well as the enriching existing biological material and data
with other types of material. Similar principles should also
be applied to software tools given that medical research is
dependent on the long-term availability and maintenance of
high-quality software tools for data processing.
Reuse of biological material and data needs to include
incentives for both sides, namely providers and accessors.
Not only should researchers have incentives to use existing
resources but resource providers also need clear incentives
to promote and facilitate the reuse of their resources. En-
forcing these principles by funding bodies, publishers, and
academic organizations will exert pressure on resource
providers to implement transparent access policies and make
their resources more easily accessible to demonstrate their
reuse. Furthermore, this should help to reduce the frag-
mentation of access procedures, which are effectively pre-
venting reuse and integration of resources on a larger scale,
as well as in biobanking.20,21
There is ongoing active development of metrics related to
these incentive systems, as witnessed by altmetrics** by
NISO{{ or CASRAI,{{ and proposals to implement transient
credit with JSON-LD.22 Micro-attribution schemes have also
been suggested to support acknowledgment of contributing to
large genomics data sets.23,24 These are further supported by
the development of technical procedures on how to reference
resources, such as BRIF25 and the CoBRA guideline26 for
biomedical and health resources. However, to date none of
these systems have been widely adopted in practice.
P: Privacy-Respecting Access
Particularly in the context of human data used in medical
research, there are three naturally competing interests: (1)
protection of privacy of individuals contributing their per-
sonal and potentially privacy-sensitive data; (2) reuse of
data to maximize return on investment into research and
society; and (3) complex ownership situation and economic
interests. These needs have been recognized by various
medical communities, as witnessed by the efforts toward
clinical trial data sharing.27
As a basis for the discussion of data protection, we need to
distinguish basic data types (Figure 6). We use the European
General Data Protection Regulation (GDPR)28 as a basis, given
that it is the most recent regulatory framework with transna-
tional impact and because of international research collabora-
tion, it is very likely to have an impact on a global scale. In the
following text, we will also use the term privacy-enhancing
technologies for a wide range of technologies that protect in-
formational privacy by eliminating or minimizing personal
data,29 e.g., coding (DT-1b) or anonymization (DT-2).
In the medical research domain, data sets are often anon-
ymized by reducing the precision of attribute values or by
removing them entirely,30 and a number of practical method-
ologies and tools doing just this have recently become avail-
able.31,32 For most people, the notion of anonymity implies that
the remaining data are no longer privacy sensitive because no
information can be traced back to or derived about the data
subjects.33 However, this is not the case for many anonymi-
zation techniques. Indeed, the frequently used simple k-
anonymity is, for example, prone to attribute disclosure.34
Even differential privacy, which is the only approach that
provides rigorous mathematically grounded privacy guaran-
tees, assumes that data cannot be totally anonymous and re-
main useful at the same time.35
Thus, the term (de facto) anonymized is preferred and
should not be understood as static and binary, but rather as a
set of various techniques for minimizing risks of privacy
breaches.33
It needs to be stressed that (de facto) anonymization is
often not needed, such as in cases where informed consent is
available for the given purpose, and other privacy-enhancing
technologies, such as coding, may be used in conjunction
with additional organizational measures. It is the responsi-
bility of the data custodian to estimate privacy risks and
adjust the technical and organizational access conditions and
procedures appropriately.
In this context, there are advantages of developing large
collections of biological material and data. Often, the greater
the number of individuals included in a data set that is to be
privacy enhanced, (1) the less information per individual has to
FIG. 4. Relationship between provenance
information and components of quality for
biological material and data.
**https://en.wikipedia.org/wiki/Altmetrics.
{{www.niso.org/topics/tl/altmetrics_initiative.
{{www.casrai.org/Dataset_Level_Metrics.
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FIG. 6. Privacy-related data types
based on GDPR. GDPR, General
Data Protection Regulation.
FIG. 5. The ideal complete
coverage of provenance infor-
mation for biological material
and associated data. Prove-
nance information is abbrevi-
ated as PI in the figure.
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be removed or perturbed to achieve the same residual risk of
reidentification30,36 and (2) the lower the risk of reidentification
when the same privacy-enhancing technology is applied.
While authors of the FAIR principles have already assumed
that accessible does not always imply ‘‘open access’’ we intro-
duce additional requirements to FAIR-Health to avoid over-
advertising and support compliance with legal requirements:
PR-1: There must be clear identification of the responsible
data controller for any given biological material and data set,
who can be contacted by data subjects (research participants)
or authorities.
PR-2: Compliance of (intended) research projects with
informed consent and the ethics approval of the research
project must be evaluated before providing access to sen-
sitive biological material and data.
PR-3: Privacy-enhancing technologies should be applied to
personal data (DT-1a) before the data can be used for research
purposes, in compliance with the data minimization principle.
PR-4: Before releasing (de facto) anonymized data (DT-2),
residual privacy risks, including risks of reidentification, must
be considered by the data controller. The residual risks must
also take into account additional safeguards, such as restricted
access with sufficient level of identity assurance.37,38
PR-5: Privacy-enhancing technologies should preserve
maximum value of data, while keeping the risks at an ac-
ceptable level.
The application of privacy-enhancing technologies on data
to be released as a whole, as opposed toper parteson the source
data subsets, should be considered. In many cases, this will
minimize effects of transforming data and reduce data pertur-
bations.
PR-6: Data provenance must be implemented in a way
that allows for identification of relevant data sets in case of
informed consent withdrawal. It should be noted that in case
of (de facto) anonymous data (DT-2), removal of data from
a specific individual may no longer be possible.
PR-7: Specifically in the case of health-related or medical
data, informed consent as well as data/material transfer
agreements (DTA/MTA) must define policy as to how to
address incidental findings and whether access to individu-
al’s own data and results is provided, as well as how they
will be accessed. In particular, the required technical and
organizational safeguards have to be described.
Policies implementing PR-7 should also consider and
adequately communicate that application of some privacy-
enhancing technologies may prevent communicating inci-
dental findings or providing access to individual’s own data/
results. This is especially important when a research project
uses (de facto) anonymized data (DT-2).
Yet, no matter how high the data protection standards are
set, there will always remain some risk of (re-)identification
of individuals and disclosure of sensitive information about
them. What is needed is the tightening of rules to protect
against privacy violation that can lead to risks such as dis-
crimination based on genetic information; the U.S. Genetic
Information Nondiscrimination Act (GINA) is a good
starting point39 that can be further elaborated upon.xx
PR-8: Legal protection must be developed and im-
plemented for individuals whose privacy has been breached
accidentally or unlawfully.
Privacy-respecting scalable data processing
and storage
The recent decade has seen the rise of cloud computing,40,41
allowing for various business models. As convenient as the
cloud infrastructures are to achieve scalable processing and
storage, they bring additional risks when used for processing
data.42,43 Several modes of operation can be implemented with
respect to data protection, where data storage and processing
can take place:
1. in private clouds41 built and operated by the data con-
troller (e.g., a biobank in our case)—this enables pro-
cessing of any type of data;
2. in an infrastructure that is contracted by way of a third
party under such conditions that enable the third-party
infrastructure to logically become part of the private in-
frastructure, thereby operating under the same liability
for both data controller and for infrastructure provider—
‘‘logically private clouds’’; and
3. in public clouds where the cloud provider does not pro-
vide any specific data protection guarantees—this is
mostly restricted to data that do not require legal pro-
tection, namely (de facto) anonymized data (DT-2) with
very low risk of reidentification (see requirement PR-4)
or nonhuman data (DT-5).
If the data controller agrees to transfer the data to the re-
searcher under a Material/Data Transfer Agreement (MTA/
DTA), the researcher has the same modes available. Modes 2
and 3 are nowadays subject to major ongoing development
from the data protection perspective. International standards in
this field recently emerged, such as ISO 27018.44 However,
their adequateness and acceptance in medical research are
largely open issues, hence the following additional require-
ments:
PR-9: Commonly-accepted policies and procurement
guidelines must be developed under conditions where the third-
party infrastructures can logically become private infrastruc-
tures suitable for storing and processing privacy-sensitive data.
PR-10: Commonly accepted guidelines must be devel-
oped for storing and processing data covered by data pro-
tection regulations on public infrastructures.
Conclusions
Life sciences generally suffer from fragmentation, while
medical research in particular suffers also from substantial
reproducibility issues. In this article, we proposed to extend
the recently developed FAIR principles to FAIR-Health
principles related to quality—namely reproducibility and
meaningfulness—by providing comprehensive provenance
information for the complete chain from a donor to biological
material to data, as well as incentives for enriching existing
resources and reusing them. Given the use of human material
and data in medical research, we also propose privacy-
protecting principles related to compliance with data pro-
tection regulations. European researchers, in collaboration
with experts from multiple domains, including legal experts,
computer science experts, and medical researchers, as well as
xxGINA provides some protection against discrimination in health
insurance, but it does not provide protection against discrimination
in life insurance and long-term care insurance.
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research participants and citizens, are now gathering to define
specific rules for a Code of Conduct for GDPR45 to ensure
compliance with the regulatory frameworks. For medical
research, all of these components called FAIR-Health are
fundamental prerequisites for effective reuse of biological
material and data.
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